

## Stroke

### Focal ischemic brain lesion

Molecular Aspects of Neurological Diseases

Philippe Lyrer  
29.05.2007

---

---

---

---

---


---

---

---

### Aim

- Close the gap !



---

---

---

---

---

---

---

---

### Overview

- What is a stroke
- Animal models
- The ischemic cascade
- Translation to clinical trials
- Diffuse subcortical ischemic lesions
- Failure of clinical trials
- Outlook

---

---

---

---

---

---

---

---

### Stroke - Definition

There are two main types of stroke

- **Ischemic stroke** 84%
  - is caused by blockage in an artery that supplies blood to the brain, resulting in a deficiency in blood flow (ischemia)
- **Hemorrhagic stroke** 16%
  - is caused by the bleeding of ruptured blood vessels (hemorrhage) in the brain 10% intracerebral, 6% subarachnoidal.

---

---

---

---

---

---

---

---

### Stroke – “biologic” Definition

During ischemic stroke, diminished blood flow initiates a series of events (called **ischemic cascade**) that may result in additional, delayed damage to brain cells

Early medical intervention can halt this process and reduce the risk for irreversible complications.

---

---

---

---

---

---

---

---

### Background Information

- 3rd most common cause of death
  - after heart attack and cancer
- Higher mortality with increasing age:
  - ≥ 60 years 2nd most common cause of death
- Men and women equally frequent
- Incidence: 150 - 200 / 100 000/year
  - Basel: 170 / 100'000/year (02-03)
  - 45-84 years old: 400 / 100 000/year

---

---

---

---


---

---

---

---

**Ischemic brain lesion: cranial computer tomography early imaging (2 hours)**



Dept. of Neuroradiology, University Hospital Basel, Switzerland

---

---

---

---


---

---

---

---

**Ischemic brain lesion: delayed cranial computer tomography (48 hours)**



Dept. of Neuroradiology, University Hospital Basel, Switzerland

---

---

---

---

---

---

---

---

**Hemorrhagic brain lesion: Cranial Computer tomography**

Exclude intracranial Hemorrhage !



Dept. of Neuroradiology, University Hospital Basel, Switzerland

---

---

---

---

---


---

---

---

## Penumbra: DWI-PWI Mismatch

Diffusion / perfusion mismatch may be a marker for territory at risk.




---

---

---

---

---

---


---

---

---

---

## Mechanism of cerebral ischemia




---

---

---

---

---

---


---

---

---

---

## Embolic arterial occlusion



- Embolic clot occlusion of the middle cerebral artery (courtesy of A.Probst, Neuropathology Basel)

---

---

---

---

---

---

---

---

---

---

## Animal models

- Rat: 4-Vessel occlusion (global)  
MCAO (focal)
  - Mouse: MCAO (focal)
  - Gerbil: CCAO (focal, global)
  - Rabbit: clot model (t-PA model)
  - Cat: cardiac arrest models
  - Dog: cardiac arrest cardiac arrest
  - Non-human primates: behavioral models
- Note: Transient vs. Permanent vessel occlusion

Lit.: Hoyte L. et al.: Exp. Neurology 2004

---

---

---

---

---

---


---

---

---

---

MCAO: Three-vessel occlusion using a micro-clip for the proximal left middle cerebral artery



Lit.: Hiroji Yanamoto, Izumi Nagata, Nobuo Hashimoto and Haruhiko Kkuchi

---

---

---

---

---

---


---

---

---

---

## MCA occlusion – permanent (autoradiography)



Lit.: Belayev L, et al. Stroke. 1996

---

---

---

---

---

---

---


---

---

---

### MCA occlusion - permanent and temporary

Permanent group   30-min group   90-min group



Yasuki Onog, Shigetaro Morkawa, Toshiro Inubushi, Hiroaki Shimizu, and Takashi Yoshimoto

---

---

---

---

---

---


---

---

### CT Schädel

Nativ

Spiral-CT mit KM



(Aufgaben: Neurologie, Universitätsklinikum Bonn, Prof. E.W. Radt)

---

---

---

---


---

---

---

---

### PET from patient with acute MCA-occlusion



- Regional hypoperfusion at 3 hours after beginning of symptoms
- By reperfusion, no lesion on CT few days later

---

---

---

---


---

---

---

---

## The penumbra concept



Baron JC Cerebrovascular Diseases 1999;9:193-201.

---

---

---

---

---

---


---

---

---

---

## „Time is Brain“



JCBFM 2000;20:1276-93.

---

---

---

---

---

---

---

---

---

---

## Perfusion Basics

- CBF - Cerebral Blood Flow (ml/100ml/min)
  - Gray matter 45-70 ml/100ml/min
  - White Matter 20-24 ml/100ml/min
- CBV - Cerebral Blood Volume (ml/100ml)
  - Gray matter 4-7 %
  - white matter 2-3%
- MTT - Mean Transit Time (seconds)
  - Mean time to traverse vasculature (NOT pixel!)
  - CBV:CBF ratio

---

---

---

---

---

---

---

---

---

---

## What happens in stroke ?

Blood supply drops suddenly threshold values:

- Cerebral blood flow values:
- 80-60 ml/min/100g: normal state
- 37-60 ml/min/100g: protein syn., selective gene exp.
- 20-36 ml/min/100g: lactic acidosis, cytotoxic edema
- 10-20 ml/min/100g: energy deficit, glutamate tox.
- 0-10 ml/min/100g: anoxic depolarisation, infarction




---

---

---

---


---

---

---

---

## Cerebral blood flow



(from Hakim; Neurology:51(supp3):S44-6)

---

---

---

---


---

---

---

---

## Magnetic resonance imaging



T2

DWI

ADC

52 y/o WF with migraines, awoke with right H/A, L hemiparesis

---

---

---

---

---

---


---

---




### Diagnostic Information in Acute Stroke: Diffusion Weighted Imaging

At 5 hours...



After 5 days...



- Diagnostic Info: Assess initial infarct by DWI
- Prognostic Info: Predict infarct growth by PWI

---

---

---

---

---

---


---

---



---

---

### Cytotoxic Edema: Diffusion Weighted Imaging



- ATP-depletion
- Na<sup>+</sup>-K<sup>+</sup> pump
- Cytotoxic edema
- Increased extracellular tortuosity
- Hindrance of water movement
- Diffusion weighted images appear bright



Moseley M.E, et al. 1990

---

---

---

---

---

---


---

---

---

---

### Penumbra: DWI-PWI Mismatch



Patient with acute occlusion of A. cerebri media

---

---

---

---

---

---

---

---

---

---

## What happens in stroke ?

Consequences are disturbance :

- neurons, glial cell, astrocytes – simultaneously
- vessel lesion
- interstitial space
- secondary damages: edema, space occupation, recanalisation injury, bleeding

---

---

---

---

---

---

---

---

## Major pathways implicated in ischaemic cell death

- excitotoxicity
- ionic imbalance
- oxidative and nitrosative stresses
- apoptotic-like mechanisms
- Disturbance of the neurovascular unit:
  - Proteolysis
  - inflammation

Lo H., et al. nature rev. 2003

---

---

---

---


---

---

---

---

## Major pathways implicated in ischemic cell death



Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5): p. 399-415.

---

---

---

---


---

---

---

---

### Major pathways implicated in ischemic cell death



Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5); p. 399-415.

RNS  
reactive  
nitrogen  
species

ROS  
reactive  
oxygen  
species

---

---

---

---

---

---


---

---

---

---

### Major pathways implicated in ischemic cell death



Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5); p. 399-415.

RNS  
reactive  
nitrogen  
species

ROS  
reactive  
oxygen  
species

---

---

---

---

---

---


---

---

---

---

### Ionic imbalance - Calcium metabolism




---

---

---

---

---

---

---


---

---

---

## Glutamate toxicity - glucose

Glutamatergic Synapse      Astrocyte      Capillary



1. At **glutamatergic synapses**, the action of glutamate is terminated by an efficient glutamate uptake system located in astrocytes.

Magistretti P., Pellerin L.; News Physiol Sci. 1999 Oct;14:177-182.  
Pyr, pyruvate; Lac, lactate; Gln, glutamine; G, G protein; PGK, phosphoglycerate kinase

---

---

---

---

---


---

---

---

## Glutamate toxicity - glucose

Glutamatergic Synapse      Astrocyte      Capillary



2. **Glutamate** is cotransported with  $\text{Na}^+$ , resulting in an increase in the intracellular concentration of  $\text{Na}^+$ , leading to the activation of the  $\text{Na}^+-\text{K}^+-\text{ATPase}$  (2a). Glutamate is converted to glutamine by glutamine synthase (2b).

Magistretti P., Pellerin L.; News Physiol Sci. 1999 Oct;14:177-182.  
Pyr, pyruvate; Lac, lactate; Gln, glutamine; G, G protein; PGK, phosphoglycerate kinase

---

---

---

---

---


---

---

---

## Glutamate toxicity - glucose

Glutamatergic Synapse      Astrocyte      Capillary



3. Activation of the  **$\text{Na}^+-\text{K}^+-\text{ATPase}$**  triggers aerobic glycolysis.

Magistretti P., Pellerin L.; News Physiol Sci. 1999 Oct;14:177-182.  
Pyr, pyruvate; Lac, lactate; Gln, glutamine; G, G protein; PGK, phosphoglycerate kinase

---

---

---

---

---

---

---


---

## Glutamate toxicity - glucose

Glutamatergic Synapse

Astrocyte

Ca<sup>2+</sup>



4 Lactate produced by the glutamate-stimulated glycolysis is released from astrocytes. A, synaptic activation; B, direct glucose uptake into neurons under basal conditions.

Magistretti P., Pellerin L.; News Physiol Sci. 1999 Oct;14:177-182.

Pyr, pyruvate; Lac, lactate; Gln, glutamine; G, G protein; PKC, phosphoglycerate kinase

---

---

---

---

---

---

---

---

---

---

## Summary of glutamate-calcium release

- K<sup>+</sup> efflux
- Excessive glutamate release and over excitation of glutamate receptors
- Ca<sup>2+</sup> release from organelles
- Ca<sup>2+</sup> influx and sequestration in the cell
- Intracellular accumulation of Ca<sup>2+</sup> and Zn<sup>2+</sup>
  - ends in activation of calmodulin dependent intracellular enzymes (phospholipases, endonucleases and protein kinases)

---

---

---

---

---

---


---

---

---

---

## Major pathways implicated in ischemic cell death



RNS  
reactive  
nitrogen  
species

ROS  
reactive  
oxygen  
species

Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci. 2003. 4(5): p. 399-415.

---

---

---

---

---

---


---

---

---

---

## Generation of oxygen and nitrogen radicals



Combination of superoxide ( $O_2^{\cdot-}$ ) and nitric oxide (NO) generates the potent radical peroxynitrite anion ( $ONOO^{\cdot-}$ ). Metal ( $Cu^+$  and  $Fe^{2+}$ ) catalysed pathways can also produce the hydroxyl radical ( $OH^{\cdot}$ ) from hydrogen peroxide ( $H_2O_2$ ).

COX - cyclooxygenase  
 GPX - glutathione peroxidase  
 NOS - nitric oxide synthase  
 SOD - superoxide dismutase  
 XO - xanthine oxidase

---

---

---

---

---

---

---

---

---


---

## apoptotic-like mechanisms Cell death pathways that are relevant to an apoptotic-like mechanism in cerebral ischaemia

**IAP**  
 inhibitors of apoptosis

**PARP**  
 poly-(ADP ribose) polymerase

**AIF**  
 Apoptosis inducing factor



**Smac**  
 Secondary mitochondria derived activator of caspase

**CAD**  
 caspase-activated deoxyribo nuclease

Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5): p. 399-415.

---

---

---

---

---

---

---

---


---

---

## apoptotic-like mechanisms Cell death pathways that are relevant to an apoptotic-like mechanism in cerebral ischaemia

1. Cytochrome c release from the mitochondria is modulated by **pro** as well as **anti-apoptotic Bcl2** family members. Cytochrome c release activates **downstream caspases** through apoptosome formation and caspase activation can be modulated by secondary mitochondria-derived activator of caspase (Smac/Diablo) indirectly through suppressing protein inhibitors of apoptosis (IAP).

**AIF**  
 Apoptosis inducing factor



**Smac**  
 Secondary mitochondria derived activator of caspase

**CAD**  
 caspase-activated deoxyribo nuclease

Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5): p. 399-415.

---

---

---

---

---

---

---

---

---

---

**apoptotic-like mechanisms Cell death pathways that are relevant to an apoptotic-like mechanism in cerebral ischaemia**

**2. Effector caspases (caspases 3 and 7) target several substrates, which dismantle the cell by cleaving homeostatic, cytoskeletal, repair, metabolic and cell signalling proteins. Caspases also activate caspase-activated deoxyribonuclease (CAD) by cleavage of an inhibitor protein (ICAD).**

**AIF**  
Apoptosis inducing factor

**Smac**  
Secondary mitochondria derived activator of caspase

**CAD**  
caspase-activated deoxyribonuclease

Protein degradation:  
• Homeostatic  
• Cytoskeletal  
• DNA repair  
• Metabolic  
• Cell signalling

Lo, E.H., T. Dalkara, and M.A. Moskowitz, *Nat Rev Neurosci*, 2003, **4**(5): p. 399-415.

---

---

---

---

---

---

---

---

**apoptotic-like mechanisms Cell death pathways that are relevant to an apoptotic-like mechanism in cerebral ischaemia**

**3. Caspase-independent cell death might also be important. One mechanism proposes that poly-(ADP ribose) polymerase (PARP) activation promotes the release of apoptosis-inducing factor (AIF), which translocates to the nucleus, binds to DNA and promotes cell death through a mechanism that awaits clarification**

**IAP**  
inhibitors of apoptosis

**PARP**  
poly-(ADP ribose) polymerase

**AIF**  
Apoptosis inducing factor

Lo, E.H., T. Dalkara, and M.A. Moskowitz, *Nat Rev Neurosci*, 2003, **4**(5): p. 399-415.

---

---

---

---

---

---

---

---

**Apoptosis**

**Nuclear pathway**  
Trophic factor withdrawal  
Jun kinase → c-Jun → c-Jun phosphorylation → Cell death genes → Apoptosis

**Non-nuclear pathway**  
Bax → Mitochondria → Cytochrome c → Apaf-1 → Caspase-9 → Caspase-3 → Apoptosis → Cellular fragmentation → Phagocytosis

Yuang & Yankner, *Nature* 2000

---

---

---

---


---

---

---

---

## Apoptosis



Yuang & Yankner, Nature 2000

---

---

---

---

---

---


---

---

---

---

## protease cascade involving members of the matrixmetalloproteinase



Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5): p. 399-415.

---

---

---

---

---

---


---

---

---

---

## Metalloproteinases



Yong et al. Nature Reviews 2001

---

---

---

---

---

---

---


---

---

---



### Schematic view of the neurovascular unit or module, and some of its components



Lo, E.H., T. Dalkara, and M.A. Moskowitz, Nat Rev Neurosci, 2003, 4(5): p. 399-415.

---

---

---

---

---

---

---

---

Cause: Perfusion deficit, CBF <20ml/100g/min, complete, partial, time-dependent

Stop of metabolism, depletion of ATP, accumulation of lactate

Breakdown of the ATP-dependent Na-K-pump, loss of electric gradient, missing re-uptake and loss of glutamate, excitotoxicity

Increase of intracellular  $Ca^{2+}$ -due to inflow of  $Ca^{2+}$  from extracellular space and release of  $Ca^{2+}$  from endoplasmatic reticulum and mitochondria

Activation of proteases, early gene expression, phospholipase A2 triggers production of arachidonic acid → cell mediators: leucotriens, adhesion molecules, platelet aggregation factor

Generation of free radicals, arachidonic acid → prostaglandin, oxidation of lipids, release of iron

Cellular edema, irreversible cellular destruction, apoptosis via programmed metabolism due to proteases and endonucleases

---

---

---

---


---

---

---

---

### Overview of the ischemic cascade



Cause: Perfusion deficit, CBF <20ml/100g/min, complete, partial, time-dependent

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Cause: Perfusion when CBF is not fully restored

Stop of metabolism, depletion of ATP, accumulation of lactate

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Cause: Perfusion when CBF is not fully restored

Stop of metabolism, depletion of ATP, accumulation of lactate

Breakdown of the ATP-dependent Na-K-pump, loss of electric gradient, missing re-uptake and loss of glutamate, excitotoxicity

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Cause: Perfusion when CBF is not fully restored

Stop of metabolism, depletion of ATP, accumulation of lactate

Breakdown of the ATP-dependent Na-K-pump, loss of

Increase of intracellular Ca<sup>2+</sup> due to inflow of Ca<sup>2+</sup> from extracellular space and release of Ca<sup>2+</sup> from endoplasmic reticulum and mitochondria

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Causes: Perfusion deficit, O<sub>2</sub> and ATP deprivation, ischemia

Stop of metabolism, depletion of ATP

Breakdown of the ATP-dependent Na<sup>+</sup>-K<sup>+</sup> pump, loss of

increase of intracellular Ca<sup>2+</sup> due to inflow of Ca<sup>2+</sup> from

Activation of proteases, early gene expression, phospholipase A2 triggers production of arachidonic acid → cell mediators: leucotriens, adhesion molecules, platelet aggregation factor

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Causes: Perfusion deficit, O<sub>2</sub> and ATP deprivation, ischemia

Stop of metabolism, depletion of ATP

Breakdown of the ATP-dependent Na<sup>+</sup>-K<sup>+</sup> pump, loss of

increase of intracellular Ca<sup>2+</sup> due to inflow of Ca<sup>2+</sup> from

Activation of proteases, early gene expression, phospholipase A2 triggers

Generation of free radicals, arachidonic acid → prostaglandin, oxidation of lipids, release of iron

---

---

---

---


---

---

---

---

## Overview of the ischemic cascade



Cellular edema, irreversible cellular destruction, apoptosis via programmed metabolism due to proteases and endonucleases

Causes: Perfusion deficit, O<sub>2</sub> and ATP deprivation, ischemia

Stop of metabolism, depletion of ATP

Breakdown of the ATP-dependent Na<sup>+</sup>-K<sup>+</sup> pump, loss of

increase of intracellular Ca<sup>2+</sup> due to inflow of Ca<sup>2+</sup> from

Activation of proteases, early gene expression, phospholipase A2 triggers

Generation of free radicals, arachidonic acid → prostaglandin, oxidation of lipids, release of iron

---

---

---

---

---

---

---

---

## The concept of so-called neuroprotection

- Neuroprotective treatment
  - Glutamat-Antagonist
    - NMDA-Receptor-Antagonist (e.g. Magnesium, Lubeluzole)
    - AMPA-Receptor-Antagonist (e.g. ZK200775)
    - Glycin-Antagonist (e.g. GV-150526A)
  - GABA-Agonist (e.g. Clomethiazol)
  - GABA-Analoga (e.g. Piracetam)
  - Calcium antagonist (e.g. Nimodipin)
  - calcium channel blockers (e.g. BMS-204352)
  - Adenosin agonist (e.g. Acadesin, Propentofyllin, Pentoxifyllin)
  - 5-HT<sub>1A</sub>-Agonist (e.g. Ipsapiron, BAY X 3702)
  - growth factors (e.g. Trifermin)
  - Membrane-stabilizer (e.g. Citicholin, Tirilazad)
- Anti-inflammatory treatment
  - Cytokin inhibitors (e.g. IL-1-Rezeptor-Antagonisten)
  - Immune modulation (e.g. Tacrolimus, Cyclosporin)
- free radical scavengers
- barbiturates

Hayko, L., J. Kauz, and A.M. Buchan. Lost in translation: taking neuroprotection from animal models to clinical trials. *Exp Neurol*. 2004. 188(2): p. 200-4.

---

---

---

---

---

---

---


---

---

---

## Treatment with thrombolysis and its therapeutic effect

OR/NNT combined endpoints (mRS1, NIHSS 1, BI\*95)  
 0–90 min: OR 2,8; NNT>4      91-180 min: OR 1,5; NNT>9  
 181-270 min: OR 1,4; NNT>21      271-360 min: OR 1,2; NNT>45



Brott et al., 2003

---

---

---

---

---

---


---

---

---

---

## The concept of so-called neuroprotection



A. Richard Green, Tim Ashwood, Tomas Odegren, David M. Jackson; *Pharmacology & Therapeutics* 100 (2003) 195–214

---

---

---

---

---

---

---

---

---

---



### What is wrong with neuroprotection ?

„Is it not erroneous to lump together infarcts of all shapes, sizes, times, severities, and locations due to various occlusions (or no occlusions or site of occlusion unknown) and trust the statisticians to make sense of it all through randomization into underpowered trials?“

Furlan AJ. Stroke 2002;33:1450-501.

---

---

---

---

---

---

---

---

### Reasons for neuroprotectants failure

- **Pharmacologic reasons**
  - pharmacologic target not relevant to humans
  - wrong dose
  - wrong treatment duration
  - unsuitable pharmacokinetics
- **Unsuitable study design**
  - Use of wrong measurements (outcomes)
  - delayed treatment
- **Statistical Power<sup>1</sup>**
  - overestimation of therapeutic effect (>10%)
  - underestimation of clinical relevant effects
- **Pathophysiological heterogeneity<sup>2</sup> of the disease**
  - no biological substrate to salvage
  - no penumbra
  - lack of reperfusion

<sup>1</sup>Stroke 2001;32:669-74; <sup>2</sup>Stroke 2002;33:1545-50.

---

---

---

---

---

---

---

---

### Future design for neuroprotective trials

- More standardized stroke syndromes for inclusion in trials
- Animal models should be standardized
- Short time window
- Salvageable tissue in the DWI/PWI MRI
- Molecule that passes BBB
- Co-administration of thrombolytic therapy

---

---

---

---


---

---


---

---

## Leucoaraiosis



JJ160139, m 61 yrs  
Hypertension



RE030736, m 66-years,  
no hypertension

---

---

---

---

---

---


---

---

---

---

## Subcortical hypertensive arteriosclerotic encephalopathy



JJ160139, m 61 yrs, hypertension

---

---

---

---

---

---


---

---

---

---

## Pathology – microscopic appearance of affected vessels (arterioles)



from A. Probst, Neuropathology, Basel

---

---

---

---

---

---


---

---

---

---

### FM, 020136, f



---

---

---

---

---

---

---

---

### Vascular Dementia - Epidemiology

- Prevalence (%) in Europe/USA:

1989 Boston	AD	8.7	VaD	0.9
1990 London		3.1		0.1
1991 Stockholm		6.0		3.0
1995 Rotterdam		4.5		1.0
1997 Odense		4.7		1.3

- Ratio AD/VaD: <math><0.1-0.5!</math>

Review, Acta Psych Scand 2001;104:4-11

---

---

---

---


---

---

---

---

### Blood pressure and risk of stroke



per 5-6mmHg diastolic or 10-12 systolic BP-elevation: 38% relative Risk increase

(Lit.: Journal of Neurology, Neurosurgery and Psychiatry. 1991; 54: 1044-1054)

---

---

---

---

---

---

---

---



**Animal models: Genetically predisposed rats**

**Spontaneously Hypertensive rats (SHR)**

**Origine:**

Okamoto at the Kyoto School of Medicine in 1963 from an outbred Wistar Kyoto male with marked elevation of blood pressure mated to female with slightly elevated blood pressure

**Characteristics:**

Hypertension, insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia.

**Spontaneously Hypertensive Stroke Prone rats (SHR-SP)**

**Characteristics:**

82 % of males will develop cerebrovascular lesions (cerebral hemorrhage or infarction) over 100 days of age.  
Hypertension, nephropathy, insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia.

---

---

---

---

---

---

---

---

---

---

**Animal models: Genetically predisposed rats**

**Anatomical abnormalities:**

- Variable branching pattern of the distal MCA
- Morphological arrangement of vascular smooth muscle cells are disorganized in the basilar artery of the SHR-SP: influence collateral circulation, rheological changes of blood flow, or vulnerability of the arterial wall to high blood pressure,
- Abnormalities in the BBB: plasma components leakage through arterioles: induce fibrinoid necrosis of small arteries, severe brain edema and lacunar infarction.
- No atheromatous lesions.

**Vascular physiology:**

- Response of the cerebral artery to substances causing endothel-dependent vasodilatation impaired in SHR-SP.

**Genetic loci involved:**

- Chromosomes 1 and 18: genes involved in blood pressure
- Chromosome 5: blood pressure independent, co-localized with genes encoding atrial and brain natriuretic factor

---

---

---

---

---

---


---

---

---

---

**Blood pressure according to different strains**



Lin J.-X. et al., Neuroreport 2001;12:1835-1839

---

---

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

### Differences between Wistar and stroke prone SHR

Smooth muscle actin staining, increased in SHR-SP with hypertrophic arteries (Anterior cerebral artery)



Lin J.-X. et al., Neuroreport 2001;12:1835-1839

---

---

---

---

---

---

---


---

---

---

### Klüver-Barrera staining of white matter in corpus callosum

Disturbed structure of the white matter in CC from SHR-SP: disarrangement of nerve fiber, marked vacuoles and disappearance of myelinated fibers



Lin J.-X. et al., Neuroreport 2001;12:1835-1839

---

---

---

---

---

---

---


---

---

---

### Appearance of white matter lesions in the brain of SHR, SHR-SP

- Normal (grade 0)
- disarrangement of the nerve fibers (grade 1)
- formation of marked vacuoles (grade 2)
- disappearance of myelinated fibers (grade 3)



Lin J.-X. et al., Neuroreport 2001;12:1835-1839

---

---

---

---

---

---




---

---

---

---

## Col4 and GFAP in normotensive and hypertensive rats




---

---

---

---

---

---

---

---

The End

---

---

---

---

---

---

---

---